Market Overview

KeyBanc: 3 Reasons Why Invacare Is No Longer A Buy

KeyBanc: 3 Reasons Why Invacare Is No Longer A Buy
Related IVC
60 Biggest Movers From Yesterday
41 Biggest Movers From Yesterday
Biocept leads healthcare gainers; Achieve Life Sciences and Revance Therapeutics among losers (Seeking Alpha)

Invacare Corporation (NYSE: IVC), a manufacturer and distributor of medical equipment used in non-acute care settings, signaled in its second-quarter earnings report a turnaround is not progressing as rapidly as expected, according to KeyBanc Capital Markets. 

The Analyst

KeyBanc Capital Markets' Matthew Mishan downgraded Invacare from Overweight to Sector Weight.

The Thesis

Invacare's earnings report does show some signs of improvement in the business, but it is not enough to support a bullish stance, Mishan said in the downgrade note. (See the analyst's track record here.) 

For example, the portable oxygen concentrator strategy hasn't gained sufficient traction to offset declines in the company's legacy products, the analyst said. The home medical equipment segment is "stable" for now, and any woes in Europe can no longer be offset by favorable foreign exchange rates, he said. 

Invacare decided in 2016 and 2017 to deprioritize low-margin products and focus on a more clinical complex portfolio, Mishan said. At the same time, the company also guided toward $28 million in annualized savings from various initiatives, and any benefits are now reflected in the company's results, he said. 

Invacare needs to show better sales acceleration moving forward for the company to hit its $100-million EBITDA target by late 2020, Mishan said. The company has shown it is making some progress, but there are simply too many "moving pieces," he said. 

Price Action

Invacare shares were trading down more than 3 percent to $16.05 at the time of publication Thursday. 

Related Links:

A Peek Into The Markets: US Stock Futures Surge Ahead Of Earnings

10 Stocks To Watch For August 16, 2018

Latest Ratings for IVC

Aug 2018KeyBancDowngradesOverweightSector Weight
May 2018KeyBancMaintainsOverweightOverweight
Feb 2018KeyBancMaintainsOverweightOverweight

View More Analyst Ratings for IVC
View the Latest Analyst Ratings

Posted-In: KeyBanc Capital Markets Matthew Mishan medical equipmentAnalyst Color Downgrades Health Care Analyst Ratings General Best of Benzinga


Related Articles (IVC)

View Comments and Join the Discussion!

Latest Ratings

EMNMorgan StanleyUpgrades90.0
DERMRaymond JamesUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Gray-market Businesses Take Advantage Of Loopholes Before 2019 Legalization

The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait